EUVIMEDEUVIMED entdecken
Multizentrische Studie

A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy

Makito Miyake, Yuki Oda, Nobutaka Nishimura, Motokiyo Yoshikawa, Keiichi Sakamoto, Yoshiaki Matsumura, Atsushi Tomioka, Yusuke Iemura, Masaomi Kuwada, Kota Iida, Takashi Iwamoto, Fumisato Maesaka und 4 weitere

Asia-Pacific Journal of Clinical Oncology · 2026

DOI: 10.1111/ajco.70080 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2026. Verfasst von Makito Miyake und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Furans, Ketones, Retroperitoneal Neoplasms. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Clinical evidence on disease characteristics and outcomes of retroperitoneal sarcoma (RPS) remains limited. Although eribulin was approved for soft tissue sarcomas in Japan in 2016, real‐world data on its use for advanced RPS are scarce. We investigated treatment patterns and survival outcomes of patients with RPS, with a particular focus on those receiving eribulin.

Methods

The database included 118 patients pathologically diagnosed with RPS between January 2000 and August 2025. Clinicopathologic data, including inflammation/nutrition markers and survival outcomes, were analyzed.

Results

Among them, 102 (86%) underwent surgical resection of the primary tumor, with a median recurrence‐free survival of 20 months and a median overall survival of 9.2 years. Well‐differentiated liposarcoma, dedifferentiated liposarcoma, leiomyosarcoma, and undifferentiated pleomorphic sarcoma were the most frequent histologic subtypes. Non‐well‐differentiated liposarcoma histology, Stage IIIA−IIIB, lower C‐reactive protein–albumin–lymphocyte index, and higher modified neutrophil–platelet score were associated with poor postoperative prognosis. Of 44 patients with unresectable RPS who received systemic therapy, 23 (52%) were treated with eribulin. In this group, complete response, partial response, and stable disease rates were 4.3%, 26%, and 35%, respectively. The most common adverse events were decreased neutrophil count (40%), peripheral neuropathy (30%), and dysgeusia (20%). Multivariate analysis showed that non‐use of eribulin and undifferentiated pleomorphic sarcoma were independently associated with worse survival in unresectable disease.

Conclusion

We separately described outcomes and treatment patterns of patients with resectable and unresectable RPS. Our findings suggest that eribulin should be considered a treatment option for unresectable RPS in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsFuransKetonesRetroperitoneal NeoplasmsSarcomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDatabases, FactualJapanPolyether PolyketidesPrognosisRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

chemotherapyinflammationoutcomeprognosisretroperitoneal sarcoma

Substanzen

Antineoplastic AgentseribulinFuransKetonesPolyether Polyketides

Autor:innen und Institutionen

  • Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
  • Department of Urology, Nara Prefecture General Medical Center, Nara, Nara, Japan.
  • Department of Urology, Nara City Hospital, Nara, Nara, Japan.
  • Department of Urology, Saiseikai Chuwa Hospital, Sakurai, Nara, Japan.
  • Department of Urology, Yamatotakada Municipal Hospital, Yamatotakada, Nara, Japan.
  • Department of Urology, Matsusaka Chuo General Hospital, Matsusaka, Mie, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Miyake, M., Oda, Y., Nishimura, N., Yoshikawa, M., Sakamoto, K., Matsumura, Y., Tomioka, A., Iemura, Y., Kuwada, M., Iida, K., Iwamoto, T., Maesaka, F., Toyoshima, Y., Fujii, T., Fujimoto, K., & Nara Urological Research and Treatment Group (NURTG) (2026). A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70080

Vancouver

Miyake M, Oda Y, Nishimura N, Yoshikawa M, Sakamoto K, Matsumura Y, et al. A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70080

BibTeX
@article{Miyake2026,
  author = {Miyake, Makito and Oda, Yuki and Nishimura, Nobutaka and Yoshikawa, Motokiyo and Sakamoto, Keiichi and Matsumura, Yoshiaki and Tomioka, Atsushi and Iemura, Yusuke and Kuwada, Masaomi and Iida, Kota and Iwamoto, Takashi and Maesaka, Fumisato and Toyoshima, Yuta and Fujii, Tomomi and Fujimoto, Kiyohide and Nara Urological Research and Treatment Group (NURTG), Nara Urological Research and Treatment Group (NURTG)},
  title = {A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1111/ajco.70080}
}
Kostenlos starten →